Search

Valrubicin

Used in the treatment of the bladder cancer, valrubicin is administered by direct infusion into the bladder.

Tolazamide

A sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide.

Momelotinib

[A261566] First approved by the FDA on September 15, 2023,[L48206] momelotinib is used to treat myelofibrosis. … [L48186] Myelofibrosis (MF) is a group of myeloproliferative neoplasms characterized by abnormal proliferative hematopoietic stem cells, leading to the release of cytokines and growth factors.

Oxaliplatin

[A797] Oxaliplatin was approved by the FDA on January 9, 2004 and is currently marketed by Sanofi-Aventis under the trademark Eloxatin®.[L47316] … [A797] However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties.

REP8839

REP8839 is a novel methionyl-tRNA synthetase (MetS) inhibitor being developed by Replidyne (GlaxoSmithKline licensed REP8839 to Replidyne in June of 2003).

Plecanatide

Plecanatide is a drug approved in January 2017 by the FDA for the treatment of chronic idiopathic constipation (CIC).

DP-VPA

DP-VPA is D-Pharm's proprietary lipid modified version of valproic acid (VPA) that demonstrate that DP-VPA is well-tolerated in patients with resistant epilepsy and has a marked effect on reducing seizure frequency.

Pivhydrazine

In 1960, it was widely used as an antidepressant agent but it is now discontinued.

Lanreotide

Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome … Lanreotide was first approved for use in the United States by the FDA on August 30, 2007.

Neisseria meningitidis group Y capsular polysaccharide tetanus toxoid conjugate antigen